Contact
searchSearch
HMP Global
Login

Kidney Cancer Resource Center

News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
From Oncology
News
Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective...
03/11/2024
Oncology
From Oncology
News
FDA Approves Belzutifan For Advanced Kidney Cancer
03/04/2024

Emry Lloyd

Emry Lloyd
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan,...
03/04/2024
Journal of Clinical Pathways
Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
Dr Rana McKay, medical oncologist at the University of California in San Diego.
Videos
Characterization of FOLH1 Expression in Renal Cell Carcinoma
04/11/2023
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate...
04/11/2023
Journal of Clinical Pathways
News
Interactive Data Visualization Tool Facilitates Shared Decision-Making in Kidney Cancer
09/21/2021
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an...
09/21/2021
Journal of Clinical Pathways
Quiz
Quiz: Disparities in Treatment Decision-Making for Kidney Cancer
09/02/2021
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are...
09/02/2021
Journal of Clinical Pathways
News
Clinical and Economic Impact of Early vs Delayed Progression After First-Line TKIs in Patients With Metastatic RCC
08/30/2021
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after...
08/30/2021
Journal of Clinical Pathways
News
Disparities in Treatment Decision-Making for Patients With Kidney Cancer
08/11/2021
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex,...
08/11/2021
Journal of Clinical Pathways
News
Real-World Patterns and Predictors of Oral Anticancer Agent Use Among Patients With Metastatic RCC
07/29/2021
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral...
07/29/2021
Journal of Clinical Pathways

Expert Insights

Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
Dr Rana McKay, medical oncologist at the University of California in San Diego.
Videos
Characterization of FOLH1 Expression in Renal Cell Carcinoma
04/11/2023
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate...
04/11/2023
Journal of Clinical Pathways
Videos
Real-World Use of Cabozantinib Plus Direct Oral Anticoagulants in RCC
04/21/2021
04/21/2021
Journal of Clinical Pathways
Videos
Patterns and Predictors of Oral Anticancer Agent Use for Metastatic RCC
03/18/2021
03/18/2021
Journal of Clinical Pathways
Videos
Real-World Treatment Sequences After First-Line Therapy in Metastatic RCC
03/18/2021
03/18/2021
Journal of Clinical Pathways
Videos
Impact of Oral Anticancer Agent Adherence on Survival Outcomes in Metastatic RCC
02/25/2021
02/25/2021
Journal of Clinical Pathways
Olivia Lynch
Interview
Where Access Breaks Down: Uncovering Persistent Disparities in Early-Stage Lung Cancer Treatment
04/21/2026
Olivia Lynch, MD, MPH
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research...
04/21/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment: Part 2
03/24/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how...
03/24/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment
03/24/2026
Rahul Mudumba, PhD, MHS
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba...
03/24/2026
Journal of Clinical Pathways
Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways
Quality Outlook
The Rising and Setting of Health Equity
02/24/2026
David Sloan, PhD; Tom Valuck, MD, JD
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating...
02/24/2026
Journal of Clinical Pathways
JJN
Interview
NSCLC Clinical Pathways in the Era of Molecular Complexity, AI, and Value-Based Care
02/20/2026
Jorge J. Nieva, MD
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest...
02/20/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology

Newsfeed

News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
News
Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective...
03/11/2024
Oncology
News
FDA Approves Belzutifan For Advanced Kidney Cancer
03/04/2024

Emry Lloyd

Emry Lloyd
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan,...
03/04/2024
Journal of Clinical Pathways
Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
News
Interactive Data Visualization Tool Facilitates Shared Decision-Making in Kidney Cancer
09/21/2021
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an...
09/21/2021
Journal of Clinical Pathways
News
Clinical and Economic Impact of Early vs Delayed Progression After First-Line TKIs in Patients With Metastatic RCC
08/30/2021
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after...
08/30/2021
Journal of Clinical Pathways
News
Disparities in Treatment Decision-Making for Patients With Kidney Cancer
08/11/2021
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex,...
08/11/2021
Journal of Clinical Pathways
News
Real-World Patterns and Predictors of Oral Anticancer Agent Use Among Patients With Metastatic RCC
07/29/2021
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral...
07/29/2021
Journal of Clinical Pathways
Conference Coverage
Nivolumab Plus Ipilimumab Cost-Effective for Intermediate or Poor Risk RCC
10/08/2020
10/08/2020
Journal of Clinical Pathways
News
How Age, Comorbidities, and Race Influence Cancer Treatment in Older Patients
05/05/2026
Rebecca Amrick
Using the US Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage database, a study identified potential gaps in geriatric oncology care among Black and Hispanic patients, older age groups, and patients with multimorbidity.
Using the US Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage database, a study identified potential gaps in geriatric oncology care among Black and Hispanic patients, older age groups, and patients with multimorbidity.
Using the US Surveillance,...
05/05/2026
Journal of Clinical Pathways
News
Liquid Biopsies Show Promise but Face Key Challenges in Older Adults
04/29/2026
Lisa Kuhns, PhD, MD
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for...
04/29/2026
Journal of Clinical Pathways
News
Just Released: 2026 Clinical Pathways Congress Agenda
04/23/2026
Danielle Sposato
Join us November 10–11, 2026 at the Four Seasons Hotel Boston as we bring together leaders across the pathways ecosystem for two days focused on turning strategy into action.
Join us November 10–11, 2026 at the Four Seasons Hotel Boston as we bring together leaders across the pathways ecosystem for two days focused on turning strategy into action.
Join us November 10–11, 2026 at...
04/23/2026
Journal of Clinical Pathways
News
Proactive Outreach for Smoking Cessation Treatment Shows Potential for Patients With Cancer
04/17/2026
Rebecca Amrick
A proactive smoking cessation program for patients with cancer shows high engagement and satisfaction among participants, but low enrollment highlights ongoing challenges with patient identification and outreach.
A proactive smoking cessation program for patients with cancer shows high engagement and satisfaction among participants, but low enrollment highlights ongoing challenges with patient identification and outreach.
A proactive smoking cessation...
04/17/2026
Journal of Clinical Pathways
News
Interventional Radiology Leads Multidisciplinary Care in Liver Cancer Treatment
04/15/2026
Lisa Kuhns, PhD, MD
Research suggests that interventional radiology is central to hepatocellular carcinoma (HCC) care at all stages.
Research suggests that interventional radiology is central to hepatocellular carcinoma (HCC) care at all stages.
Research suggests that...
04/15/2026
Journal of Clinical Pathways
News
Short-Duration Venetoclax Plus Decitabine Shows Comparable AML Outcomes
04/09/2026
Grace Taylor, MS, MA
A shortened 10-day venetoclax regimen combined with decitabine delivers comparable remission rates with fewer infections in older patients with newly diagnosed acute myeloid leukemia (AML).
A shortened 10-day venetoclax regimen combined with decitabine delivers comparable remission rates with fewer infections in older patients with newly diagnosed acute myeloid leukemia (AML).
A shortened 10-day venetoclax...
04/09/2026
Journal of Clinical Pathways
News
FDA Approves Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer
04/08/2026
Grace Taylor, MS, MA
The US Food and Drug Administration's (FDA) approval of relacorilant plus nab-paclitaxel offers a new survival-improving option for patients with platinum-resistant ovarian cancer following prior bevacizumab therapy.
The US Food and Drug Administration's (FDA) approval of relacorilant plus nab-paclitaxel offers a new survival-improving option for patients with platinum-resistant ovarian cancer following prior bevacizumab therapy.
The US Food and Drug...
04/08/2026
Journal of Clinical Pathways
Conference Coverage
Community-Engaged Strategies Reduce Cancer Care Delays and Advance Health Equity
03/27/2026
Hannah Musick
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
Targeted Education Improves Cancer Pain Management in Community Hospitals
03/27/2026
Grace Taylor, MS, MA
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
SEER Analysis Highlights Risk Factors for Advanced DLBCL at Diagnosis
03/27/2026
Grace Taylor, MS, MA
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis...
03/27/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Disparities in Treatment Decision-Making for Kidney Cancer
09/02/2021
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are...
09/02/2021
Journal of Clinical Pathways
Quiz
Quiz: Oral Anticancer Agent Use for Metastatic RCC
05/05/2021
05/05/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use